je.st
news
Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
2016-09-15 14:31:48| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y. New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting Study Achieved Primary and All Key Secondary Endpoints KENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Language: English read more
Tags: with
type
people
added
Category:Biotechnology and Pharmaceuticals